Answers are grounded in this paper and cite their sources.
Neurodegenerative diseases are gradually developing diseases of progressive loss of structure and function of neurons; due to the complex and multifaceted pathophysiology of neurodegenerative diseases, there is a great challenge in their therapeutic management. Pathological mechanisms associated with these diseases include protein aggregation abnormalities, impaired autophagy, neuronal apoptosis, oxidative stress, mitochondrial dysfunction, and neuroinflammation in Parkinson’s disease, Huntington's disease, and amyotrophic lateral sclerosis [2,3,5,8]. The progression of these disorders is also complicated by the blood–brain barrier (BBB), which can rigorously control the movement of molecules across the barrier and restrict the delivery of many therapeutic agents [1,4,7,14]. In this context, the development of efficient drug delivery devices towards the brain has become a key research direction in the fields of pharmaceutical and nanomedicine. The highly-branched nanoscale macromolecules called dendrimers have gained significant research interest as drug delivery systems due to their well-defined structure, surface functionality, internal cavities useful for accommodating drug molecules, the ability to conjugate and decorate their surface, and the ability to self-assemble into distinct particles [21-24]. The terminal functional groups enable the chemical modification of PPI dendrimers, and the nanoscale structure can be tailored to develop approaches in drug delivery and targeting, which makes them very interesting for neurological applications [23,29]. Recent research has shown that surface-functionalized PPI dendrimers can enhance their delivery into the brain and their cellular uptake, while retaining some of the advantages concerning the highly cationic dendritic systems [31,32]. The use of a natural product payload is a further objective that can be investigated in this platform, and convolivine, a compound found in Convolvulus species, could be a potential natural product payload since experimental evidence for the use of a convolivine-loaded PPI dendrosome remains to be established [33]. In the present review, the pathological basis of neurodegenerative diseases, the role of the BBB in restricting the entry of drugs into the CNS, structural and pharmaceutical properties of dendrimers and PPI dendrimers are discussed, and the rationale behind the development of propylene imine-loaded convolivine dendrosomes is discussed at last. In particular, formulation development and characterization, particle size, PDI, zeta potential, Cellular uptake, BBB transport, biological safety, morphology, drug-loading, entrapment efficiency, and in vitro release of the drug are given special mention. The review also analyzes existing evidence for the feasibility of dendrimer-mediated CNS delivery, significant research gaps, and future directions that need to be explored to improve the usage of PPI-based dendrosomal systems. Taking all this into consideration, propylene imine-loaded convolivine dendrosomes are a new, interesting research idea to improve brain targeting, but more systematic disease-appropriate, pharmaceutical, pharmacokinetic, and toxicological studies are required to confirm their therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Gautam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: